CD8A and neoplasm: The combination of melphalan with adoptive cell therapy also significantly prolongs survival in mice with advanced B-cell lymphomas or colorectal cancer, where melphalan enhances immune response by increasing cytokine release, DC activation and the potentiation of both endogenous CD8+ T cells and adoptively transferred tumor-specific CD4+ T cells.13